BergaVia (Bergamot Polyphenolic Fraction)

BergaVia is a standardized Bergamot Polyphenolic Fraction (BPF) containing flavonoids such as naringenin, brutieridin, and melitidin that actively inhibit HMG-CoA reductase, the same enzyme targeted by statin drugs. Clinical trials demonstrate it simultaneously lowers LDL and triglycerides while raising HDL, making it a multi-target intervention for metabolic health.

Origin & History

BergaVia is a branded polyphenolic extract derived from the albedo (white inner peel) of bergamot fruit (Citrus bergamia Risso et Poit.), native to Calabria, Italy. The patented extraction process involves enzymatic treatment, ultrafiltration, polyphenol adsorption onto resins, and spray-drying to produce a standardized powder containing ~40% total polyphenols with reduced furocoumarins (<400 mg/kg).

Historical & Cultural Context

No historical or traditional medicine context was documented in the research sources. Bergamot appears to be utilized primarily in modern phytocomplex extraction rather than having established use in traditional medicine systems like Ayurveda or TCM.

Health Benefits

• Reduces total cholesterol by 22.2% in hypercholesterolemic patients (human RCT, n=80)
• Lowers LDL cholesterol by 24.2% after 30 days of supplementation (clinical trial evidence)
• Decreases triglycerides by 34.7% in clinical studies (human RCT data)
• Increases HDL cholesterol by 27.6% (clinical trial in hypercholesterolemic patients)
• Supports liver fat reduction through modulation of lipid metabolism genes (preclinical evidence only)

How It Works

BergaVia's key flavonoids brutieridin and melitidin structurally mimic statins by competitively inhibiting HMG-CoA reductase, thereby reducing endogenous cholesterol synthesis in hepatocytes. Naringenin and other polyphenols activate AMPK (AMP-activated protein kinase), which upregulates LDL receptor expression on liver cells to enhance clearance of circulating LDL particles. Additionally, these polyphenols reduce oxidative stress via Nrf2 pathway activation and suppress hepatic VLDL secretion, contributing to the observed triglyceride-lowering effect.

Scientific Research

A randomized, double-blind, placebo-controlled trial (n=80) in hypercholesterolemic patients demonstrated significant lipid improvements with 500 mg/day BergaVia for 30 days. While PMIDs were not specified in the research dossier, preclinical studies show BPF downregulates SREBP-1C and upregulates PPARα, UCP2, ACOX1, and ATG7 in hepatocyte models, though additional human RCTs are lacking.

Clinical Summary

A double-blind, placebo-controlled RCT (n=80) in hypercholesterolemic patients demonstrated that BergaVia supplementation for 30 days reduced total cholesterol by 22.2%, LDL by 24.2%, and triglycerides by 34.7%, while increasing HDL by 27.6%. These findings represent statistically significant outcomes from a well-controlled human trial, lending moderate-to-strong evidence for lipid-modifying efficacy. Evidence is currently concentrated in a relatively small number of trials, and independent large-scale replication would further strengthen the confidence level. The existing data is promising and mechanistically coherent, though it should not yet be equated with the extensive evidence base supporting pharmaceutical statins.

Nutritional Profile

BergaVia is a standardized bergamot polyphenolic fraction (BPF) extract derived from Citrus bergamia fruit juice, not a whole food ingredient, so conventional macronutrient and micronutrient profiles are not applicable in the traditional sense. The bioactive composition is the defining characteristic: standardized to contain approximately 25–40% total polyphenols by dry weight. Key identified polyphenolic compounds include brutieridin (a statin-like flavonoid glycoside, present at approximately 3–5% of extract weight) and melitidin (another HMG-CoA reductase-inhibiting flavonoid, approximately 2–4%), which are unique to bergamot and largely absent in other citrus fruits. Additional flavonoids include neoeriocitrin (~8–12%), naringin (~10–15%), neohesperidin (~8–12%), poncirin, rhoifolin, and neodesmin. These flavanone glycosides contribute to lipid-modulating and antioxidant activity. Hydroxycinnamic acids such as ferulic acid and caffeic acid derivatives are also present in minor concentrations (<1%). The extract contains negligible protein (<1%), negligible fat (<0.5%), and minimal carbohydrates primarily from flavonoid glycoside sugar moieties. Fiber content is not nutritionally significant in the concentrated extract form. Bioavailability notes: flavanone glycosides such as neoeriocitrin and naringin undergo hydrolysis by colonic microbiota to release aglycones (hesperetin, naringenin), which are then absorbed; absolute oral bioavailability of these aglycones is estimated at 15–40%. Brutieridin and melitidin demonstrate direct enzyme-inhibitory bioactivity relevant to cholesterol synthesis. The polyphenolic matrix may benefit from food co-ingestion to enhance micellar solubilization and absorption.

Preparation & Dosage

The clinically studied dosage for BergaVia BPF powder (standardized to ~40% total polyphenols) is 500 mg per day, typically taken as 1 capsule for 30 days. No data on other forms or dosage ranges were provided in clinical research. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Red yeast rice, Plant sterols, Niacin, Omega-3 fatty acids, Artichoke leaf extract

Safety & Interactions

BergaVia is generally well-tolerated at studied doses, with most adverse events limited to mild gastrointestinal discomfort such as nausea or loose stools in sensitive individuals. Because its active compounds inhibit HMG-CoA reductase, concurrent use with prescription statins (e.g., atorvastatin, rosuvastatin) may produce additive lipid-lowering effects and should be supervised by a physician to avoid excessive LDL reduction or myopathy risk. Bergamot polyphenols may also interact with CYP3A4-metabolized drugs similarly to grapefruit, potentially raising plasma levels of certain medications including immunosuppressants and calcium channel blockers. Safety data during pregnancy and lactation is insufficient, so use is not recommended in those populations without medical supervision.